IL103584A - Treatment of protozoan infection with bivalent salt of bicarcin - Google Patents
Treatment of protozoan infection with bivalent salt of bicarcinInfo
- Publication number
- IL103584A IL103584A IL10358492A IL10358492A IL103584A IL 103584 A IL103584 A IL 103584A IL 10358492 A IL10358492 A IL 10358492A IL 10358492 A IL10358492 A IL 10358492A IL 103584 A IL103584 A IL 103584A
- Authority
- IL
- Israel
- Prior art keywords
- bacitracin
- treatment
- infection
- compositions
- zinc
- Prior art date
Links
- 108010001478 Bacitracin Proteins 0.000 title claims abstract description 178
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 title claims abstract description 140
- 229930184125 bacitracin Natural products 0.000 title claims abstract description 111
- 229960003071 bacitracin Drugs 0.000 title claims abstract description 102
- 238000011282 treatment Methods 0.000 title claims abstract description 67
- 150000003839 salts Chemical class 0.000 title claims abstract description 26
- 229910052751 metal Inorganic materials 0.000 title claims abstract description 22
- 239000002184 metal Substances 0.000 title claims abstract description 22
- 208000028172 protozoa infectious disease Diseases 0.000 title claims abstract description 5
- 241001465754 Metazoa Species 0.000 claims abstract description 20
- 241000224528 Tritrichomonas Species 0.000 claims abstract description 7
- 241001058196 Tritrichomonas foetus Species 0.000 claims abstract description 6
- UCRLQOPRDMGYOA-DFTDUNEMSA-L zinc;(4r)-4-[[(2s)-2-[[(4r)-2-[(1s,2s)-1-amino-2-methylbutyl]-4,5-dihydro-1,3-thiazole-4-carbonyl]amino]-4-methylpentanoyl]amino]-5-[[(2s,3s)-1-[[(3s,6r,9s,12r,15s,18r,21s)-3-(2-amino-2-oxoethyl)-18-(3-aminopropyl)-12-benzyl-15-[(2s)-butan-2-yl]-6-(carbox Chemical compound [Zn+2].C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC([O-])=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@H](CC([O-])=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 UCRLQOPRDMGYOA-DFTDUNEMSA-L 0.000 claims description 76
- 208000015181 infectious disease Diseases 0.000 claims description 49
- 239000000203 mixture Substances 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 26
- 108010016899 bacitracin A Proteins 0.000 claims description 11
- -1 Ni2* Chemical compound 0.000 claims description 10
- 241000224527 Trichomonas vaginalis Species 0.000 claims description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 5
- 239000003981 vehicle Substances 0.000 claims description 5
- 241000224466 Giardia Species 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 4
- 241000295636 Cryptosporidium sp. Species 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 235000010980 cellulose Nutrition 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 8
- 235000019359 magnesium stearate Nutrition 0.000 claims 4
- 208000010489 Entamoebiasis Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 241000282414 Homo sapiens Species 0.000 abstract description 7
- 241000224432 Entamoeba histolytica Species 0.000 abstract description 5
- 229940007078 entamoeba histolytica Drugs 0.000 abstract description 4
- 241000223936 Cryptosporidium parvum Species 0.000 abstract description 2
- 241000224526 Trichomonas Species 0.000 abstract description 2
- 244000037640 animal pathogen Species 0.000 abstract 1
- 244000052637 human pathogen Species 0.000 abstract 1
- 239000012678 infectious agent Substances 0.000 abstract 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 25
- 229960000282 metronidazole Drugs 0.000 description 25
- 229940079593 drug Drugs 0.000 description 22
- 239000003814 drug Substances 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- 201000010099 disease Diseases 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 244000045947 parasite Species 0.000 description 15
- 241000283690 Bos taurus Species 0.000 description 12
- 208000005448 Trichomonas Infections Diseases 0.000 description 12
- 206010044620 Trichomoniasis Diseases 0.000 description 12
- 208000031513 cyst Diseases 0.000 description 12
- 241000224489 Amoeba Species 0.000 description 11
- 239000003826 tablet Substances 0.000 description 11
- 230000003071 parasitic effect Effects 0.000 description 10
- 206010011732 Cyst Diseases 0.000 description 9
- 241000287107 Passer Species 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000007789 gas Substances 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 239000003995 emulsifying agent Substances 0.000 description 8
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 210000003812 trophozoite Anatomy 0.000 description 8
- 244000309464 bull Species 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 230000000968 intestinal effect Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 229910021645 metal ion Inorganic materials 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 230000003816 axenic effect Effects 0.000 description 6
- 239000005662 Paraffin oil Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 231100000636 lethal dose Toxicity 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 208000004881 Amebiasis Diseases 0.000 description 4
- 206010001980 Amoebiasis Diseases 0.000 description 4
- 241000224431 Entamoeba Species 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 208000010362 Protozoan Infections Diseases 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- 239000006265 aqueous foam Substances 0.000 description 4
- 244000309466 calf Species 0.000 description 4
- 238000011037 discontinuous sequential dilution Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000006260 foam Substances 0.000 description 4
- 239000001282 iso-butane Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 229910052725 zinc Inorganic materials 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 3
- 150000004958 5-nitroimidazoles Chemical class 0.000 description 3
- 206010001986 Amoebic dysentery Diseases 0.000 description 3
- 241000223782 Ciliophora Species 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 206010012741 Diarrhoea haemorrhagic Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000010668 complexation reaction Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 208000001848 dysentery Diseases 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 201000004792 malaria Diseases 0.000 description 3
- 238000004242 micellar liquid chromatography Methods 0.000 description 3
- 230000004899 motility Effects 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000001593 sorbitan monooleate Substances 0.000 description 3
- 235000011069 sorbitan monooleate Nutrition 0.000 description 3
- 229940035049 sorbitan monooleate Drugs 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 206010003591 Ataxia Diseases 0.000 description 2
- 208000008953 Cryptosporidiosis Diseases 0.000 description 2
- 206010011502 Cryptosporidiosis infection Diseases 0.000 description 2
- 241000223935 Cryptosporidium Species 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 241000224467 Giardia intestinalis Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000004554 Leishmaniasis Diseases 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000001117 Theileriasis Diseases 0.000 description 2
- 201000005485 Toxoplasmosis Diseases 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 239000010775 animal oil Substances 0.000 description 2
- 201000008680 babesiosis Diseases 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 210000004081 cilia Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229910003460 diamond Inorganic materials 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- IBXPYPUJPLLOIN-UHFFFAOYSA-N dimetridazole Chemical compound CC1=NC=C(N(=O)=O)N1C IBXPYPUJPLLOIN-UHFFFAOYSA-N 0.000 description 2
- 229960000946 dimetridazole Drugs 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 210000003495 flagella Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 201000006592 giardiasis Diseases 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000003108 parasitologic effect Effects 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 150000003751 zinc Chemical class 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- FCLQHQCOKGKLHR-PPPWKGACSA-N (4R)-5-[[(2R,3R)-1-[[(3S,9R,12R,15R,18R,21R)-3-(2-amino-2-oxoethyl)-18-(3-aminopropyl)-12-benzyl-15-[(2R)-butan-2-yl]-6-(carboxymethyl)-9-(1H-imidazol-5-ylmethyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclopentacos-21-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-[[(2R)-4-methyl-2-[[2-[(2R)-2-methylbutanoyl]-1,3-thiazole-4-carbonyl]amino]pentanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@@H](C)[C@@H](NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CC(C)C)NC(=O)c1csc(n1)C(=O)[C@H](C)CC)C(=O)N[C@@H]1CCCCNC(=O)[C@H](CC(N)=O)NC(=O)C(CC(O)=O)NC(=O)[C@@H](Cc2cnc[nH]2)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](NC(=O)[C@@H](CCCN)NC1=O)[C@H](C)CC FCLQHQCOKGKLHR-PPPWKGACSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- KKAJSJJFBSOMGS-UHFFFAOYSA-N 3,6-diamino-10-methylacridinium chloride Chemical compound [Cl-].C1=C(N)C=C2[N+](C)=C(C=C(N)C=C3)C3=CC2=C1 KKAJSJJFBSOMGS-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000000230 African Trypanosomiasis Diseases 0.000 description 1
- 206010001981 Amoebic infections Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 101100371682 Caenorhabditis elegans cyk-3 gene Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 101100298295 Drosophila melanogaster flfl gene Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000272496 Galliformes Species 0.000 description 1
- 241001490752 Gregarinasina Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- NTAFJUSDNOSFFY-UHFFFAOYSA-N Ipronidazole Chemical compound CC(C)C1=NC=C([N+]([O-])=O)N1C NTAFJUSDNOSFFY-UHFFFAOYSA-N 0.000 description 1
- 241000186783 Lactobacillus vaginalis Species 0.000 description 1
- 206010024652 Liver abscess Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 241000192041 Micrococcus Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 206010058667 Oral toxicity Diseases 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 241001442539 Plasmodium sp. Species 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 208000007123 Pulmonary Atelectasis Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 101150003725 TK gene Proteins 0.000 description 1
- 208000025371 Taste disease Diseases 0.000 description 1
- 206010043298 Testicular atrophy Diseases 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 241000223996 Toxoplasma Species 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940023020 acriflavine Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 201000010788 atrophy of testis Diseases 0.000 description 1
- 108010016893 bacitracin B Proteins 0.000 description 1
- 108010016876 bacitracin F Proteins 0.000 description 1
- ABQNCKJDMKENIG-UHFFFAOYSA-N bacitracin F Natural products CCC(C)C(NC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)c1csc(n1)C(=O)C(C)CC)C(=O)NCCCCC2NC(=O)C(CC(=O)N)NC(=O)C(CC(=O)O)NC(=O)C(Cc3cnc[nH]3)NC(=O)C(Cc4ccccc4)NC(=O)C(NC(=O)C(CCCN)NC2=O)C(C)CC ABQNCKJDMKENIG-UHFFFAOYSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 231100001256 chronic oral toxicity Toxicity 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 150000004696 coordination complex Chemical class 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 244000079386 endoparasite Species 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 229940085435 giardia lamblia Drugs 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229940116364 hard fat Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 208000029080 human African trypanosomiasis Diseases 0.000 description 1
- 244000000011 human parasite Species 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229950000107 ipronidazole Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000019656 metallic taste Nutrition 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 231100000243 mutagenic effect Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000036438 mutation frequency Effects 0.000 description 1
- 231100000376 mutation frequency increase Toxicity 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000002352 nonmutagenic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 244000000042 obligate parasite Species 0.000 description 1
- ZHALDANPYXAMJF-UHFFFAOYSA-N octadecanoate;tris(2-hydroxyethyl)azanium Chemical compound OCC[NH+](CCO)CCO.CCCCCCCCCCCCCCCCCC([O-])=O ZHALDANPYXAMJF-UHFFFAOYSA-N 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 231100000418 oral toxicity Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000011146 organic particle Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 230000007824 polyneuropathy Effects 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 244000000040 protozoan parasite Species 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 230000005801 respiratory difficulty Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000004767 rumen Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 201000002612 sleeping sickness Diseases 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- NWZBFJYXRGSRGD-UHFFFAOYSA-M sodium;octadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCCCOS([O-])(=O)=O NWZBFJYXRGSRGD-UHFFFAOYSA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 229940100515 sorbitan Drugs 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 231100001044 testicular atrophy Toxicity 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940029614 triethanolamine stearate Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Compounds Of Unknown Constitution (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78566691A | 1991-10-31 | 1991-10-31 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL103584A0 IL103584A0 (en) | 1993-03-15 |
| IL103584A true IL103584A (en) | 1996-06-18 |
Family
ID=25136245
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL10358492A IL103584A (en) | 1991-10-31 | 1992-10-29 | Treatment of protozoan infection with bivalent salt of bicarcin |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US5300491A (de) |
| EP (1) | EP0669831B1 (de) |
| JP (1) | JPH07500601A (de) |
| AT (1) | ATE190847T1 (de) |
| AU (1) | AU664721B2 (de) |
| CA (1) | CA2122598C (de) |
| CZ (1) | CZ105794A3 (de) |
| DE (1) | DE69230835T2 (de) |
| EE (1) | EE9400161A (de) |
| ES (1) | ES2147554T3 (de) |
| IL (1) | IL103584A (de) |
| LT (1) | LT3158B (de) |
| LV (1) | LV10392B (de) |
| NZ (1) | NZ244966A (de) |
| RU (1) | RU94021356A (de) |
| SK (1) | SK49794A3 (de) |
| WO (1) | WO1993008822A1 (de) |
| ZA (1) | ZA928421B (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5620953A (en) * | 1994-07-27 | 1997-04-15 | Merck & Co., Inc. | Antiprotozoal cyclic tetrapeptides |
| US6955908B1 (en) * | 2000-06-21 | 2005-10-18 | Lambl Barbara B | Organism associated with nongonococcal urethritis |
| EP1365745A2 (de) | 2001-02-15 | 2003-12-03 | King Pharmaceuticals, Inc. | Stabilisierte pharmazeutische und schilddrüsenhormon-zusammensetzungen und herstellungsverfahren |
| US7101569B2 (en) | 2001-08-14 | 2006-09-05 | Franz G Andrew | Methods of administering levothyroxine pharmaceutical compositions |
| US8992999B2 (en) * | 2004-06-25 | 2015-03-31 | Alltech, Inc. | Methods and compositions for controlling parasitic infections of animals |
| FR2890559B1 (fr) * | 2005-09-13 | 2011-06-24 | Galderma Sa | Mousses dermatologiques a base de metronidazole et emulsions pour la preparation |
| FR2890560B1 (fr) * | 2005-09-13 | 2011-06-24 | Galderma Sa | Mousses dermatologiques a base de metronidazole et emulsions pour leur preparation |
| DE102008027375A1 (de) * | 2008-06-09 | 2009-12-10 | Henkel Ag & Co. Kgaa | Bacitracin-Metall-Komplexe als Bleichkatalysatoren |
| KR20120097379A (ko) * | 2009-10-28 | 2012-09-03 | 셀리아 파마슈티칼즈 에이피에스 | 바시트라신 항생제 |
| PL434639A1 (pl) * | 2020-07-13 | 2022-01-17 | Adifeed Spółka Z Ograniczoną Odpowiedzialnością | Weterynaryjna kompozycja do leczenia i/lub zapobiegania chorób wywoływanych przez pierwotniaki u zwierząt, zawierająca olejek eteryczny oraz sposób jej wytwarzania |
| PL246688B1 (pl) * | 2020-07-13 | 2025-02-24 | Adifeed Spolka Z Ograniczona Odpowiedzialnoscia | Weterynaryjna kompozycja do leczenia i/lub zapobiegania chorób wywoływanych przez pierwotniaki u zwierząt zawierająca olejek eteryczny oraz sposób jej wytwarzania |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2594374A (en) * | 1949-10-11 | 1952-04-29 | Usa | Streptomycin-polymyxin-bacitracin composition |
| US2676134A (en) * | 1951-04-27 | 1954-04-20 | Commercial Solvents Corp | Therapeutic composition of neomycin and bacitracin |
| US2803584A (en) * | 1953-12-16 | 1957-08-20 | Commercial Solvents Corp | Zinc bacitracin-containing troche |
| US2903357A (en) * | 1958-06-13 | 1959-09-08 | Grain Processing Corp | Bacitracin product and processes utilizing nickel compounds |
| US3021217A (en) * | 1958-06-13 | 1962-02-13 | Grain Processing Corp | Bacitracin product and processes utilizing cobalt compounds |
| US2985533A (en) * | 1958-06-13 | 1961-05-23 | Grain Processing Corp | Bacitracin product and processes utilizing manganese compounds |
| US4101539A (en) * | 1977-10-17 | 1978-07-18 | Imc Chemical Group, Inc. | Bacitracin recovery process |
| US4693992A (en) * | 1985-08-26 | 1987-09-15 | International Minerals & Chemical Corp. | Bacitracin-metal-polyether antibiotic complexes |
| US5061689A (en) * | 1986-12-24 | 1991-10-29 | Bioderm, Inc. | Zinc bacitracin containing wound dressing |
-
1992
- 1992-10-23 US US07/967,471 patent/US5300491A/en not_active Expired - Lifetime
- 1992-10-29 IL IL10358492A patent/IL103584A/en not_active IP Right Cessation
- 1992-10-30 WO PCT/NO1992/000179 patent/WO1993008822A1/en not_active Ceased
- 1992-10-30 LT LTIP223A patent/LT3158B/lt not_active IP Right Cessation
- 1992-10-30 JP JP5508337A patent/JPH07500601A/ja active Pending
- 1992-10-30 SK SK497-94A patent/SK49794A3/sk unknown
- 1992-10-30 ES ES92923108T patent/ES2147554T3/es not_active Expired - Lifetime
- 1992-10-30 DE DE69230835T patent/DE69230835T2/de not_active Expired - Lifetime
- 1992-10-30 EP EP92923108A patent/EP0669831B1/de not_active Expired - Lifetime
- 1992-10-30 RU RU94021356/14A patent/RU94021356A/ru unknown
- 1992-10-30 CZ CZ941057A patent/CZ105794A3/cs unknown
- 1992-10-30 AT AT92923108T patent/ATE190847T1/de not_active IP Right Cessation
- 1992-10-30 NZ NZ244966A patent/NZ244966A/en not_active IP Right Cessation
- 1992-10-30 ZA ZA928421A patent/ZA928421B/xx unknown
- 1992-10-30 AU AU29161/92A patent/AU664721B2/en not_active Expired
- 1992-10-30 CA CA002122598A patent/CA2122598C/en not_active Expired - Lifetime
- 1992-10-31 LV LVP-92-177A patent/LV10392B/en unknown
-
1994
- 1994-11-23 EE EE9400161A patent/EE9400161A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE69230835D1 (de) | 2000-04-27 |
| RU94021356A (ru) | 1996-08-10 |
| NZ244966A (en) | 1995-05-26 |
| CA2122598A1 (en) | 1993-05-13 |
| CZ105794A3 (en) | 1994-12-15 |
| EE9400161A (et) | 1996-02-15 |
| EP0669831A1 (de) | 1995-09-06 |
| LTIP223A (en) | 1994-06-15 |
| LT3158B (en) | 1995-01-31 |
| EP0669831B1 (de) | 2000-03-22 |
| LV10392B (en) | 1995-08-20 |
| ATE190847T1 (de) | 2000-04-15 |
| SK49794A3 (en) | 1995-06-07 |
| AU664721B2 (en) | 1995-11-30 |
| ES2147554T3 (es) | 2000-09-16 |
| US5300491A (en) | 1994-04-05 |
| CA2122598C (en) | 2000-06-20 |
| LV10392A (lv) | 1995-02-20 |
| DE69230835T2 (de) | 2000-11-02 |
| ZA928421B (en) | 1993-05-14 |
| WO1993008822A1 (en) | 1993-05-13 |
| IL103584A0 (en) | 1993-03-15 |
| AU2916192A (en) | 1993-06-07 |
| JPH07500601A (ja) | 1995-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH08231410A (ja) | コクシジウム症軽減剤及びそれを含有する飼料 | |
| EP0669831B1 (de) | Behandlung von protozoalen infekten mit bacitracin | |
| EP0311195B1 (de) | Verhinderung von Schwingeltoxikose bei pflanzenfressenden Tieren | |
| CN109512998A (zh) | 含氧碳氢衍生物的酯化衍生物作为多粘菌素的协同增效剂的应用 | |
| AU2017371050B2 (en) | Methods and compositions for prevention and treatment of apicomplexan infections | |
| Purba et al. | A study about protective effect of Brevibacillus laterosporus texasporus culture on broiler chickens infected with Salmonella pullorum | |
| SK94297A3 (en) | New applications of lysozyme dimer | |
| EP0548558A2 (de) | Potentierende Tenside enthaltende Zusammensetzungen zur Behandlung von Erkrankungen bei Säugetieren | |
| Alqayim et al. | The study of biogenic iron oxide nanoparticles effects on iron status in male rabbits infected with T. evansi. | |
| JPH05201864A (ja) | 免疫賦活・感染防御剤及びその製造方法 | |
| Siben et al. | Studying efficiency of the method of treating nematodoses in sheep | |
| NO312008B1 (no) | Anvendelse av et toverdig metallsalt av bacitracin for fremstilling av et medikament for behandling av protozoinfeksjon | |
| CN119174768A (zh) | 盐酸氯丙嗪在制备抗急性肝胰腺坏死病药物中的应用 | |
| WO1997005867A1 (en) | Treatment of trichomonal infections with ditiocarb or disulfiram | |
| Jang et al. | Anticoccidial Effect of CS 32 compounds against Eimeria tenella infection in chickens | |
| RU2695069C1 (ru) | Способ лечения крупного рогатого скота при букстонеллёзе | |
| RU2665586C1 (ru) | Способ профилактики и лечения цыплят-бройлеров при кокцидиозах | |
| EP1330253B1 (de) | Verwendung der bioaktiven fraktion aus dem urindestillat der kuh ("go mutra") zur verstärkung der wirksamkeit von anti-infektiva, anti-krebsmitteln und ernährungsmitteln | |
| JPH04178333A (ja) | 抗コクシジウム剤 | |
| US20230270810A1 (en) | Veterinary compositions for the treatment and/or prevention of protozoan diseases and methods of preparation thereof | |
| US20230270809A1 (en) | Veterinary compositions for the treatment and/or prevention of protozoan diseases and methods of preparation thereof | |
| US20230263752A1 (en) | Veterinary compositions for the treatment and/or prevention of protozoan diseases and methods of preparation thereof | |
| JPS639492B2 (de) | ||
| JPS6026091B2 (ja) | コクシジウム病予防治療剤 | |
| Shorbagy et al. | Sh. A. Seddiek, Mohamed M. El |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| RH | Patent void |